Pay in 4 interest-free payments of $5.49 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Receptor Selectivity IGF-1 LR3: Primarily binds the IGF-1 receptor with high affinity
Retatrutides structure is optimized for tight albumin binding while still allowing it to activate all three target receptors
Activated T cells utilize aerobic glycolysis for their own growth and effector functions, but glucose deprivation or metabolic competition by tumour cells in the TME limits aerobic glycolysis of tumour-infiltrating T cells and inhibits T cells from producing effectors and antitumor responses
Tirzepatide, characterized by its ability to selectively bind and activate receptors for the intestinal hormones GIP and GLP-1, has been tested in numerous clinical studies and is already currently authorized in several countries for the treatment of type 2 diabetes and obesity
Among people eligible for treatment, 33.1% (95% CI, 31.4-34.8), 28.1% (95% CI, 26.4-29.8) and 26.2% (95% CI, 24.6-27.9) met the exclusion criteria for tirzepatide, liraglutide and semaglutide, respectively
